[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Crinetics Pharmaceuticals (CRNX) reporting person Dana Pizzuti executed option exercises and open-market sales on 10/01/2025. The Form 4 shows a stock option exercise for 5,000 shares at an exercise price of $16.89, creating 5,000 underlying shares. The same day, 5,000 shares were sold in open-market transactions under a Rule 10b5-1 trading plan at a volume-weighted average price of $41.81 (range $41.34–$42.16). Following the reported transactions, the reporting person directly owned 66,270 shares. The filer corrected a prior Form 4 that had misstated post-transaction ownership as 96,270 shares; the correction clarifies the true direct ownership.

Positive

• Adopted Rule 10b5-1 plan execution for the sale on 10/01/2025, indicating pre-planned transactions
• Option exercise of 5,000 shares at $16.89, establishing shares without relying solely on open-market purchases

Negative

• Correction to prior Form 4 required: prior filing misstated post-transaction ownership as 96,270 instead of 66,270
• Sale of 5,000 shares reduced direct holdings to 66,270, a disclosure investors may view as insider liquidity

Insights

Corporate Governance Analyst

Insider exercised options and sold an equal number of shares under a Rule 10b5-1 plan on 10/01/2025.

The reporting person exercised a 5,000-share option at $16.89, creating immediate beneficial ownership and then sold 5,000 shares in open-market trades at a $41.81 VWAP under a pre-existing Rule 10b5-1 plan. This sequence (exercise then sale) is a routine liquidity event where proceeds likely exceed the exercise cost on the disclosed prices.

The filing also corrects an earlier reporting error that overstated post-transaction ownership as 96,270 shares; the corrected post-transaction direct holding is 66,270 shares, which is important for accurate insider ownership records and disclosure compliance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pizzuti Dana

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Med and Dev Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M		5,000	A	$16.89	71,270(1)	D
Common Stock	10/01/2025		S(2)		5,000	D	$41.81(3)	66,270	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.89	10/01/2025		M			5,000	(4)	10/10/2032	Common Stock	5,000	$0	79,042	D

Explanation of Responses:

1. On September 4, 2025, the Reporting Person filed a Form 4 (the "Prior Form 4") which inadvertently reported that, following the transactions reported in the Prior Form 4, the Reporting Person directly owned 96,270 shares of the Issuer's common stock. In fact, the Reporting Person directly owned 66,270 shares of the Issuer's common stock following the transactions reported in the Prior Form 4.

2. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.

3. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $41.81 per share. The range of sales prices on the transaction date was $41.34 to $42.16 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

4. The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CRNX reporting person Dana Pizzuti disclose?

On 10/01/2025 Ms. Pizzuti exercised a 5,000-share option at $16.89 and sold 5,000 shares in open-market trades at a VWAP of $41.81 under a Rule 10b5-1 plan.

How many shares does Dana Pizzuti own after the transactions in the Form 4?

The corrected Form 4 reports direct ownership of 66,270 shares following the transactions.

Why was a correction filed to a prior Form 4 for CRNX?

The prior Form 4 incorrectly reported post-transaction ownership as 96,270 shares; the current filing corrects that to 66,270 shares.

At what prices were the shares sold and what was the price range?

The shares were sold at a volume-weighted average price of $41.81 with a reported range of $41.34 to $42.16 on the transaction date.

Was the sale discretionary or pre-planned?

The sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2025.